During the last session, Viking Therapeutics Inc. (NASDAQ:VKTX)’s traded shares were 3.3 million, with the beta value of the company hitting 0.66. At the end of the trading day, the stock’s price was $20.90, reflecting an intraday loss of -4.39% or -$0.96. The 52-week high for the VKTX share is $25.72, that puts it down -23.06 from that peak though still a striking 90.33% gain since the share price plummeted to a 52-week low of $2.02. The company’s market capitalization is $2.11B, and the average intraday trading volume over the past 10 days was 3.99 million shares, and the average trade volume was 4.90 million shares over the past three months.
Viking Therapeutics Inc. (VKTX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.50. VKTX has a Sell rating from 0 analyst(s) out of 11 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 10 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.19.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Viking Therapeutics Inc. (NASDAQ:VKTX) trade information
Viking Therapeutics Inc. (VKTX) registered a -4.39% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.39% in intraday trading to $20.90 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -9.84%, and it has moved by 6.91% in 30 days. Based on these gigs, the overall price performance for the year is 858.72%. The short interest in Viking Therapeutics Inc. (NASDAQ:VKTX) is 12.03 million shares and it means that shorts have 3.68 day(s) to cover.
The consensus price target of analysts on Wall Street is $33.00, which implies an increase of 36.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $24.00 and $40.00 respectively. As a result, VKTX is trading at a discount of -91.39% off the target high and -14.83% off the low.
Viking Therapeutics Inc. (VKTX) estimates and forecasts
Statistics show that Viking Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Viking Therapeutics Inc. (VKTX) shares have gone up 414.78% during the last six months, with a year-to-date growth rate less than the industry average at 2.22% against 11.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 17.40% this quarter and then jump 9.50% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -2.50%. While earnings are projected to return -25.80% in 2023, the next five years will return 40.00% per annum.
VKTX Dividends
Viking Therapeutics Inc. is due to release its next quarterly earnings between July 25 and July 31. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Viking Therapeutics Inc. (NASDAQ:VKTX)’s Major holders
Viking Therapeutics Inc. insiders own 6.24% of total outstanding shares while institutional holders control 46.86%, with the float percentage being 49.99%. FMR, LLC is the largest shareholder of the company, while 170 institutions own stock in it. As of Mar 30, 2023, the company held over 10.92 million shares (or 10.94% of all shares), a total value of $181.86 million in shares.
The next largest institutional holding, with 5.28 million shares, is of State Street Corporation’s that is approximately 5.29% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $87.93 million.
Also, the Mutual Funds coming in first place with the largest holdings of Viking Therapeutics Inc. (VKTX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 2.23 million shares. This amounts to just over 2.85 percent of the company’s overall shares, with a $20.97 million market value. The same data shows that the other fund manager holds slightly less at 0.95 million, or about 1.22% of the stock, which is worth about $8.96 million.
